CTI-Medidata partner to adopt Remote Source Review in clinical trials
Category: #health  By Saipriya Iyer  Date: 2020-07-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

CTI-Medidata partner to adopt Remote Source Review in clinical trials

CTI Clinical Trial and Consulting Services will reportedly adopt Remote Source Review of Medidata. Medidata is the end-to-end solutions provider to support the clinical trials. This contract research organization will use the service to upgrade the remote monitoring & document review process for various global studies, including projects related to COVID-19.

The coronavirus pandemic has increased the burden on medical professionals in developing drugs or vaccines due to travel restrictions and limited access to the clinical research sites. Medidata has been supporting various researchers in advancing the clinical trials during the unprecedented times. The company significantly aligns its imaging workflow solution to remotely, securely, and rapidly assist researchers in source document review and critical document acquisition.

According to Medidata’s co-founder and co-CEO, Glen de Vries, the company has strategized upon developing & deploying the technology that is necessary to ensure high discoveries. It is excited to partner with CTI to advance the clinical trials to treat various patients suffering from infectious diseases and cancer. The support services offered by the company will considerably lead to medical progress and help tackle the pandemic during this crucial period.

Remote Source Review of Medidata is a quick-to-implement technology that is built on its Rave Imaging system. The solution has been deployed already in over 15,000 clinical sites. It is valuable for use especially when clinical studies have critical timelines. It also helps the researchers when there are no secured options to de-identify, review, collect, and redact PII (Personally Identifiable Information). Additionally, it improves the CRA (clinical research associate) productivity by lowering travel costs and time.

As per the statement made by Timothy Schroeder, CTI’s founder and CEO, standardizing trials with Medidata technology and improving the remote monitoring capabilities are highly critical during the ongoing coronavirus pandemic. The company is targeting to reduce the disruptions to research, accelerate the virtual trial management, ensure data collection & integrity, and remotely manage source documents.

Source credit:

https://www.businesswire.com/news/home/20200708005231/en/Medidata-Partners-CTI-Remote-Source-Review-Clinical



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
By Saipriya Iyer

Boehringer Ingelheim, a pharmaceutical company, has recently announced the enrollment of 1st patient in its Phase 3 InPedILD™ trial. The trial will evaluate the dose and safety profile of nintedanib among childre...

Medtronic to turn Hyderabad into R&D hub with $160.3M investment
Medtronic to turn Hyderabad into R&D hub with $160.3M investment
By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company s...

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
By Saipriya Iyer

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s terminat...